| The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis G Steinbach, PM Lynch, RKS Phillips, MH Wallace, E Hawk, GB Gordon, ... New England Journal of Medicine 342 (26), 1946-1952, 2000 | 3241 | 2000 |
| Pancreatic cancer D Li, K Xie, R Wolff, JL Abbruzzese The Lancet 363 (9414), 1049-1057, 2004 | 2703 | 2004 |
| Phase II trial of curcumin in patients with advanced pancreatic cancer N Dhillon, BB Aggarwal, RA Newman, RA Wolff, AB Kunnumakkara, ... Clinical cancer research 14 (14), 4491-4499, 2008 | 1559 | 2008 |
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ... Journal of Clinical Oncology 24 (16), 2505-2512, 2006 | 1312 | 2006 |
| Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer T Arumugam, V Ramachandran, KF Fournier, H Wang, L Marquis, ... Cancer research 69 (14), 5820-5828, 2009 | 1007 | 2009 |
| Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy GR Varadhachary, EP Tamm, JL Abbruzzese, HQ Xiong, CH Crane, ... Annals of surgical oncology 13, 1035-1046, 2006 | 985 | 2006 |
| Metastatic patterns in adenocarcinoma KR Hess, GR Varadhachary, SH Taylor, W Wei, MN Raber, R Lenzi, ... Cancer 106 (7), 1624-1633, 2006 | 947 | 2006 |
| Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus MM Hassan, LY Hwang, CJ Hatten, M Swaim, D Li, JL Abbruzzese, ... Hepatology 36 (5), 1206-1213, 2002 | 944 | 2002 |
| The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells W Wang, JL Abbruzzese, DB Evans, L Larry, KR Cleary, PJ Chiao Clinical Cancer Research 5 (1), 119-127, 1999 | 944 | 1999 |
| A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. JL Abbruzzese, R Grunewald, EA Weeks, D Gravel, T Adams, B Nowak, ... Journal of Clinical Oncology 9 (3), 491-498, 1991 | 904 | 1991 |
| Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head DB Evans, GR Varadhachary, CH Crane, CC Sun, JE Lee, PWT Pisters, ... Journal of clinical oncology 26 (21), 3496-3502, 2008 | 848 | 2008 |
| Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up … HW Lo, SC Hsu, W Xia, X Cao, JY Shih, Y Wei, JL Abbruzzese, ... Cancer research 67 (19), 9066-9076, 2007 | 793 | 2007 |
| Antidiabetic therapies affect risk of pancreatic cancer D Li, SCJ Yeung, MM Hassan, M Konopleva, JL Abbruzzese Gastroenterology 137 (2), 482-488, 2009 | 767 | 2009 |
| Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway Z Wang, Y Li, D Kong, S Banerjee, A Ahmad, AS Azmi, S Ali, ... Cancer research 69 (6), 2400-2407, 2009 | 746 | 2009 |
| Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group–directed intergroup trial … PA Philip, J Benedetti, CL Corless, R Wong, EM O'Reilly, PJ Flynn, ... Journal of clinical oncology 28 (22), 3605, 2010 | 731 | 2010 |
| Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis D Wei, X Le, L Zheng, L Wang, JA Frey, AC Gao, Z Peng, S Huang, ... Oncogene 22 (3), 319-329, 2003 | 699 | 2003 |
| Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma CJ Bruns, CC Solorzano, MT Harbison, S Ozawa, R Tsan, D Fan, ... Cancer research 60 (11), 2926-2935, 2000 | 668 | 2000 |
| Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. FR Spitz, JL Abbruzzese, JE Lee, PW Pisters, AM Lowy, CJ Fenoglio, ... Journal of Clinical Oncology 15 (3), 928-937, 1997 | 654 | 1997 |
| Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial HQ Xiong, A Rosenberg, A LoBuglio, W Schmidt, RA Wolff, J Deutsch, ... Journal of clinical oncology 22 (13), 2610-2616, 2004 | 653 | 2004 |
| A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma JR Hecht, R Bedford, JL Abbruzzese, S Lahoti, TR Reid, RM Soetikno, ... Clinical Cancer Research 9 (2), 555-561, 2003 | 651 | 2003 |
